Draft Genetic Testing Policies - Blue Advantage

Blue Cross and Blue Shield of Alabama partners with AIM Specialty Health®, an independent company, to administer genetic testing solutions for our customers. 

AIM is our business associate and has agreed to follow our privacy and security policies regarding the confidentiality and protection of your personal health information.

Draft Genetic Testing Policies

Effective for dates of service on and after March 11, 2023, the changes in the document below will apply to the AIM Genetic Testing Clinical Appropriateness Guidelines. Part of AIM's semi-annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.

Summary of Changes to AIM Genetic Testing Clinical Appropriateness Guidelines Effective March 11, 2023

To continue to the AIM Specialty Health website to view genetic testing policies, click "Accept” below.

Comment on Draft Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. 

Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. 

Comments are accepted for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:

Blue Cross Blue Shield of Alabama
Attn: Health Management - Medical Policy
P.O. Box 995
Birmingham, AL 35298-0001

Fax: 205-220-0878